13F Pro Quality Score

37.5/100

Rank #2,231 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

55.0/100

Profitability

30.0/100

Balance Sheet

13.7/100

Earnings Quality

51.5/100

Free Cash Flow

30.0/100

Institutional Flow

49.1/100

Revenue Scale

30.0/100

Dilution Risk

50.1/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Unusual Activity in TFX

Events flagged as statistical outliers against TFX's own multi-year baseline — not fixed dollar thresholds.

TFX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for TELEFLEX INC (TFX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TFX at 37.5/100 on a 32-signal composite quality model, placing it at rank #2,231 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (13.7) and profitability (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), TELEFLEX INC reports quarterly revenue of $570.3M, net income of $99.7M, free cash flow of $77.9M. Top institutional holders of TFX by reported 13-F value include BlackRock, Jupiter Topco, T. Rowe Price Investment Management, based on the most recent SEC filings. TFX trades on the NYSE exchange and files with the SEC under CIK 96943. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TFX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TELEFLEX INC directly from SEC EDGAR. TELEFLEX INC's 13F Pro composite quality score has ranged between 31 and 63 since 2021, currently 37.5 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

Fun facts about TELEFLEX INC

Quirks, history, and lore behind TFX — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. medical device company · mid-cap · listed on the NYSE · headquartered in Pennsylvania.
  • 2
    The Numbers
    Annual revenue in the range of roughly $3 billion, with products sold to hospitals and clinicians in over 100 countries.
  • 3
    The History
    Founded in the 1940s, it spent decades as a diversified industrial company before pivoting hard into single-use medical devices — catheters, introducers, and all things vascular.
  • 4
    The Secret
    Its bread and butter is critical care and surgical access — the unglamorous but essential gear that keeps patients alive during procedures, like laryngoscopes and chest drainage systems.
  • 5
    The Lore
    Its UroLift system — a minimally invasive treatment for enlarged prostates — became one of its fastest-growing product lines and a genuine urologist favorite.
  • 6
    The Giveaway
    The ticker is three letters that sound like a phone company, but this Wayne, Pennsylvania firm is all about vascular access, anesthesia, and surgical devices — and that UroLift is hard to forget.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$570.3M

Net Income

Q2 2026

$99.7M

Free Cash Flow

Q2 2026

$77.9M

ROIC

Q2 2026

5.0%

D/E Ratio

Q2 2026

1.03

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+17.2% YoY
$1.99BFY 2025
FY22 $2.79BFY23 $1.71BFY24 $1.70BFY25 $1.99B

Net Income

-1399.8% YoY
$-905.6MFY 2025
FY22 $363.1MFY23 $356.3MFY24 $69.7MFY25 $-905.6M

Operating Income

+14.2% YoY
$118.4MFY 2025
FY22 $499.7MFY23 $258.7MFY24 $103.7MFY25 $118.4M

EPS (Diluted)

-1468.2% YoY
$-20.25FY 2025
FY22 $7.68FY23 $7.53FY24 $1.48FY25 $-20.25

Total Assets

-2.1% YoY
$6.95BFY 2025
FY22 $6.93BFY23 $7.53BFY24 $7.10BFY25 $6.95B

Total Debt

+53.1% YoY
$2.84BFY 2025
FY22 $1.89BFY23 $1.99BFY24 $1.86BFY25 $2.84B

Get alerted when TFX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TELEFLEX INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of TFX

Companies Similar to TFX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MMED

MiniMed Group, Inc.

43
AI score
Similar quality profile · 5 shared holders
TNDM

TANDEM DIABETES CARE INC

40
AI score
Similar quality profile · 12 shared holders
INGN

Inogen Inc

33
AI score
Similar quality profile · 2 shared holders
INNV

InnovAge Holding Corp.

51
AI score
Similar quality profile · 3 shared holders
PTCT

PTC THERAPEUTICS, INC.

38
AI score
Similar quality profile · 13 shared holders
ACHC

Acadia Healthcare Company, Inc.

40
AI score
Similar quality profile · 11 shared holders
SUPN

SUPERNUS PHARMACEUTICALS, INC.

42
AI score
Similar quality profile · 7 shared holders
AVNS

AVANOS MEDICAL, INC.

36
AI score
Similar quality profile · 6 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put TFX on your watchlist

Track score changes the day TELEFLEX INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is TFX a good stock to buy?

13F Pro's AI-powered analysis of TELEFLEX INC (TFX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TFX are available on the TFX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TFX is classified as a mid company.

Which hedge funds own TFX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TFX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TELEFLEX INC's investment landscape.